Cargando…
Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature
Duodenocaval fistula (DCF) is a very rare condition and is associated with a 41.1% of mortality rate. Although ingested foreign bodies, peptic ulcer disease and radiotherapy are often the etiologies described, only three patients have been described who developed DCF after bevacizumab therapy. We re...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257793/ https://www.ncbi.nlm.nih.gov/pubmed/37309550 http://dx.doi.org/10.1093/jscr/rjad329 |
_version_ | 1785057366732963840 |
---|---|
author | Giordano, Alessio Moroni, Francesco Gosmar, Alessandra Passagnoli, Federico Jeong, Juhye Menici, Francesco Baraghini, Maddalena Mirasolo, Vita M Campiglia, Laura Michelagnoli, Stefano Cantafio, Stefano |
author_facet | Giordano, Alessio Moroni, Francesco Gosmar, Alessandra Passagnoli, Federico Jeong, Juhye Menici, Francesco Baraghini, Maddalena Mirasolo, Vita M Campiglia, Laura Michelagnoli, Stefano Cantafio, Stefano |
author_sort | Giordano, Alessio |
collection | PubMed |
description | Duodenocaval fistula (DCF) is a very rare condition and is associated with a 41.1% of mortality rate. Although ingested foreign bodies, peptic ulcer disease and radiotherapy are often the etiologies described, only three patients have been described who developed DCF after bevacizumab therapy. We report a case of a 58-year-old woman with a history of ovarian neoplasia and subsequent surgical treatments, adjuvant radiotherapy and chemotherapy with bevacizumab with the appearance of a spontaneous DCF after 6 months at the end of this therapy. The multidisciplinary approach between oncologist and vascular surgeon together with the support of the anesthesiology team allowed the DFC to be treated surgically through the suture of the inferior vena cava and the duodenal breach. The patient was discharged on the 14th postoperative day and we found no postoperative morbidities both immediately and after 30 and 60 days. |
format | Online Article Text |
id | pubmed-10257793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102577932023-06-12 Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature Giordano, Alessio Moroni, Francesco Gosmar, Alessandra Passagnoli, Federico Jeong, Juhye Menici, Francesco Baraghini, Maddalena Mirasolo, Vita M Campiglia, Laura Michelagnoli, Stefano Cantafio, Stefano J Surg Case Rep Case Report Duodenocaval fistula (DCF) is a very rare condition and is associated with a 41.1% of mortality rate. Although ingested foreign bodies, peptic ulcer disease and radiotherapy are often the etiologies described, only three patients have been described who developed DCF after bevacizumab therapy. We report a case of a 58-year-old woman with a history of ovarian neoplasia and subsequent surgical treatments, adjuvant radiotherapy and chemotherapy with bevacizumab with the appearance of a spontaneous DCF after 6 months at the end of this therapy. The multidisciplinary approach between oncologist and vascular surgeon together with the support of the anesthesiology team allowed the DFC to be treated surgically through the suture of the inferior vena cava and the duodenal breach. The patient was discharged on the 14th postoperative day and we found no postoperative morbidities both immediately and after 30 and 60 days. Oxford University Press 2023-06-10 /pmc/articles/PMC10257793/ /pubmed/37309550 http://dx.doi.org/10.1093/jscr/rjad329 Text en Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Giordano, Alessio Moroni, Francesco Gosmar, Alessandra Passagnoli, Federico Jeong, Juhye Menici, Francesco Baraghini, Maddalena Mirasolo, Vita M Campiglia, Laura Michelagnoli, Stefano Cantafio, Stefano Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
title | Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
title_full | Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
title_fullStr | Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
title_full_unstemmed | Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
title_short | Duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
title_sort | duodenocaval fistula after bevacizumab therapy: case presentation and complete overview of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257793/ https://www.ncbi.nlm.nih.gov/pubmed/37309550 http://dx.doi.org/10.1093/jscr/rjad329 |
work_keys_str_mv | AT giordanoalessio duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT moronifrancesco duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT gosmaralessandra duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT passagnolifederico duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT jeongjuhye duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT menicifrancesco duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT baraghinimaddalena duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT mirasolovitam duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT campiglialaura duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT michelagnolistefano duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature AT cantafiostefano duodenocavalfistulaafterbevacizumabtherapycasepresentationandcompleteoverviewoftheliterature |